Get notified of page updates
Sign Up for FORCE
Newsletters
The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
Clinicaltrials.gov identifier:
NCT04191135
Study Contact Information:
For additional information, please contact:
Toll Free Number: 1-888-577-8839 or email: Trialsites@merck.com
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
About the Study
This study will look at how people with advanced () respond to different combinations of drugs. The study will look at two different treatment periods:
- Initial period: during this initial study period, participants will receive a combination of chemotherapy and drugs. Participants with stable cancer or an improvement will be able to continue to the next part of the study.
- Followup period: Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead plus a type of known as a during the follow-up period.
NOTE: This study is no longer enrolling patients.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To: